drugset / Trial / NCT03547024

A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol

NCT03547024

Phase 1 Completed 14 enrolled Janssen-Cilag International NV
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to determine the effect of JNJ-55308942: 1) high dose at steady state on the single dose pharmacokinetics of a cocktail containing selective probes of cytochrome P450 (CYP) enzymes (CYP3A, CYP2D6 and CYP2C19) in healthy adult participants (Part 1); 2) high dose at steady state on the single dose pharmacokinetics of a combination oral contraceptive containing levonorgestrel and ethinyl estradiol in healthy female participants (Part 2); and 3) low dose at steady state on the single dose pharmacokinetics of a cocktail containing selective probes of CYP enzymes (CYP3A, CYP2D6 and CYP2C19) in healthy adult participants (Part 3).

Timeline

Start
2018-06-08
Primary completion
2018-08-30
Completion
2018-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 30 mg Oral
Subject Levonorgestrel/Ethinyl Estradiol Unknown Oral
Subject Midazolam Small molecule 2 mg Oral
Subject Omeprazole Other / unclassified 20 mg Oral
Subject ZANVIPIXANT Small molecule Oral

Indications

No indication recorded.